Company intelligence / Profile preview

AxeroVision, Inc.

Carlsbad, California, USAprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

AxeroVision completed a Phase 2 trial for AXR-270 in 2021, showing positive results in 129 patients with dry eye disease associated with meibomian gland dysfunction. Both AXR-270 0.2% and 2% demonstrated excellent safety profiles and were well-tolerated. The company was planning a Phase 3 trial with approximately 800 patients before being acquired by CS Pharmaceuticals in July 2023.

Therapeutic areas: Ophthalmology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

BRM421

Phase 3

Indications: Dry eye syndromes, Xerophthalmia

Beyond the preview

Go deeper on AxeroVision, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxeroVision, Inc..

Explore the full profile